Wellington Management Group LLP Invests $15.19 Million in Immix Biopharma, Inc. $IMMX

Wellington Management Group LLP acquired a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,473,409 shares of the company’s stock, valued at approximately $15,191,000.

Several other large investors have also recently added to or reduced their stakes in the business. Blue Owl Capital Holdings LP acquired a new stake in Immix Biopharma in the 2nd quarter worth about $4,511,000. LGT Fund Management Co Ltd. increased its stake in shares of Immix Biopharma by 233.3% during the 1st quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after acquiring an additional 291,594 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new position in shares of Immix Biopharma during the 2nd quarter valued at about $913,000. Janus Henderson Group PLC lifted its holdings in shares of Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after acquiring an additional 880,434 shares during the period. Finally, Eventide Asset Management LLC purchased a new position in shares of Immix Biopharma during the 4th quarter worth about $13,331,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Lifesci Capital began coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 target price for the company. Bank of America assumed coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Needham & Company LLC began coverage on Immix Biopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price on the stock. Finally, HC Wainwright boosted their price target on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Immix Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $21.29.

Immix Biopharma Price Performance

NASDAQ:IMMX opened at $13.91 on Tuesday. The business’s 50-day moving average is $11.10 and its two-hundred day moving average is $9.85. The firm has a market capitalization of $995.12 million, a PE ratio of -15.81 and a beta of 0.20. Immix Biopharma, Inc. has a 12 month low of $1.94 and a 12 month high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Equities analysts anticipate that Immix Biopharma, Inc. will post -0.74 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.